ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") today announced the completion of XenoTherapeutics' ("Xeno") previously announced acquisition of ESSA (the "Acquisition"). Xeno...

ESSA Pharma Inc. (NASDAQ: EPIX) ("ESSA" or the "Company") is pleased to announce that its Securityholders (as defined below) have approved the acquisition of all of the issued and outstanding...

SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, Sept. 30, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, in connection with its previously...

Shareholders expected to receive approximately $0.12 per share in cash upon closing of transaction and up to approximately $0.14 per CVR under revised terms Further Adjourns Special Meeting to...

Adjournment to provide time for continued discussions regarding possible revised financial terms of transaction with XenoTherapeutics SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, Sept. 10, 2025...

SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, August 25, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) announced on August 14, 2025 that, in connection with the...

SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, August 14, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, in connection with the Company’s...

SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, August 6, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, following the Company’s receipt of an...

SOUTH SAN FRANCISCO, USA AND VANCOUVER, CANADA, July 23, 2025 - ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that, in connection with its previously announced...

The following questions and answers address briefly some questions that holders of common shares (“Common Shares”, and the holders of such Common Shares, the “Shareholders”) of ESSA Pharma...

ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) today announced that it has entered into a definitive agreement (the “Business Combination Agreement”) with XenoTherapeutics...

Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, May 8, 2025 /CNW/ - ESSA Pharma Inc. ("ESSA," or...

ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a pharmaceutical company that, prior to the discontinuation of its clinical trials and development programs, has been focused on...

Company continues to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 11, 2025 /CNW/ - ESSA Pharma Inc. ("ESSA,"

Company has initiated a process to explore and review strategic options focused on maximizing shareholder value SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Dec. 17, 2024 /CNW/ - ESSA...

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility...

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of...

ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate cancer, today announced that the...

On track to report updated Phase 1 masofaniten plus enzalutamide dose escalation data in patients with mCRPC naïve to second generation antiandrogens in the second half of 2024 Presentation of Phase

ESSA Pharma Inc. ("ESSA," or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC naïve to second generation...

ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today announced that...

ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to...

Combination of masofaniten plus enzalutamide continues to be well tolerated with deep and durable reductions in PSA in Phase 1 dose escalation in patients with mCRPC, including 81% of patients...